Clinical Trials Logo

Clinical Trial Summary

A prospective study that investigates the impact of circadian rhythm disturbances due to daylight saving time transitions on migraine patients. The Primary aim is to investigate the impact of springtime DST (March 12 2023 at 2 AM on Sunday) on sleep metrics in patients with migraine headaches. Secondary aim is to examine the association between incidence of migraine headaches and sleep metrics with time transitions. Participants will be provided with a Withings non-wearable/contactless sleep tracker, which will be placed under the mattress for a period of 4 weeks (2 weeks before and 2 weeks after) during daylight saving time transition in March, 2023. Withings Health Mate app will be downloaded to the participant's smartphone to collect Sleep Data. Headache diaries will be provided to log the details of the migraines during the study period. Morningness - eveningness questionnaire (MEQ) will be used to categorize subjects on the chronotype spectrum.


Clinical Trial Description

This is a prospective study that investigates the impact of circadian rhythm disturbances due to time transitions on migraine patients. We will seek data analytics assistance to gather the list of subjects who meet the inclusion and exclusion criteria. A thorough review of the electronic medical records will be performed by the PIs to identify the appropriate participants. The Research coordinator will contact the subjects over the phone and discuss the study details. We will follow the numerical order (data as received by the analytics team) and stop contacting the subjects once we reach the target sample size of 50. Interested subjects will be invited to the study visit for formal consenting and the explanation of the study procedure. This study is designed to analyze the sleep metrics (total sleep time, sleep efficiency, sleep onset, and wake up time) in migraine patients with daylight saving spring transition. We will collect the demographics, information regarding migraine headache and Chrono type data to perform required data analysis at OSF HealthCare Illinois Neurological Institute/University of Illinois College of Medicine at Peoria. Study subjects will be established clinic patients at OSF HealthCare INI neurological institute with a diagnosis of episodic migraines. A total of 50 subjects will be recruited in this study. Inclusion criteria: 1. Age 18 years and older 2. Episodic migraine diagnosis based on ICHD 3 criteria 3. Subjects with smart phone who can download and use the Health Mate app available on iOS14 and higher and Android 8.0 and higher (Cannot be set up from a computer) 4. Subjects that can commit to sleep on the same bed/mattress every night during the study period 5. Subjects that can commit not to use sleep aids (either prescription or over the counter sleep aids) or sedating medications (sedating anti-depressants, benzodiazepines, anti-histamines, anti-psychotics or gabapentinoids) that assist with sleep onset during the study period. Exclusion criteria: 1. Patients who do not meet ICHD-3 diagnostic criteria for migraine 2. Patients with migraine diagnosis who are suspected or confirmed to have active medication overuse headaches during the study period. 3. Patients who regularly use sleep aids (either prescription or over the counter sleep aids) or sedating medications (sedating anti-depressants, benzodiazepines, anti-histamines, anti-psychotics or gabapentinoids) to assist with sleep onset. 4. Participants who are planning to initiate new treatment for sleep disorders during the study period. 5. Subjects who participate in shift work. The PI, Co PI and statisticians shall be the only individuals who will access data. The data will be de-identified at the source and no PHI shall remain connected to any subject's name, date of birth, medical record number, or any other personal information that could tie back to patients once the study is completed. Withings, under the mattress sleep tracker, will be utilized to collect the sleep metrics in our study https://www.withings.com/us/en/sleep/shop?gclid=CjwKCAjwvNaYBhA3EiwACgndgn_LudRfkDgfsTm9vTfPy IaDs77O7c55PKJa0WZ3W4E0HFqwbIgLhBoCUIwQAvD_BwE&gclsrc=aw.ds The non-wearable/contactless sleep tracker will be placed under the mattress for a period of 4 weeks (2 weeks before and 2 weeks after) during daylight saving time transition in March, 2023. The device was validated for the detection of sleep apnea; a couple of sleep metrics showed good correlation with the gold standard polysomnogram (PSG) (Total sleep time and sleep efficiency). The Withings sleep tracking mat overestimated TST by 25.8 minutes (PSG - 366.6 (61.2) and Withings device 392.4 (67.2) minutes), acceptable precision. The device estimated sleep efficiency very well when compared to the PSG [PSG - 82.5% and Withings device 82.6%]. The app will be downloaded to the participant's smartphone. The Research Coordinator will contact the subjects who meet inclusion and exclusion criteria to explain the study procedure and obtain informed consent. Subjects will be taught how to download the app and send the data to the study personal at the initial visit. The non-wearable tracking device and the mobile app will be provided free of cost. Mobile app download data includes patient related information (demographics) and sleep metrics. Headache diaries will be provided to log the details of the migraines during the study period. Morningness - eveningness questionnaire (MEQ) will be used to categorize subjects on the chronotype spectrum. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05742191
Study type Observational
Source OSF Healthcare System
Contact Sasikanth Gorantla, MD
Phone 3096244000
Email Sasikanth.Gorantla@osfhealthcare.org
Status Recruiting
Phase
Start date February 6, 2023
Completion date June 1, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT06047457 - A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults Phase 3
Completed NCT02569853 - DFN-11 Injection in Episodic Migraine With or Without Aura Phase 3
Completed NCT00719134 - The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache Phase 4
Completed NCT03700320 - Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine Phase 3
Terminated NCT04936061 - Transnasal Cooling for Migraine N/A
Recruiting NCT05042037 - Probiotics as Adjunctive Migraine Prophylaxis N/A
Recruiting NCT05281770 - Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
Recruiting NCT04628429 - CGRP Inhibition, Autonomic Function, and Migraine
Active, not recruiting NCT05028569 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine Phase 3
Withdrawn NCT01257893 - Aspirin Resistance in Women With Migraine N/A
Recruiting NCT06051604 - Mi-Helper Transnasal Cooling for Acute Treatment of Migraine N/A
Completed NCT03132233 - Energy for the Brain N/A
Completed NCT03939312 - Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine Phase 3
Completed NCT03927144 - Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients Phase 4
Recruiting NCT06248671 - Prophylactic Treatment With Atorvastatin for Episodic Migraine. Phase 2
Recruiting NCT05711394 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine Phase 3
Recruiting NCT05449145 - The Effects of Vitamin D Plus Omega-3 Polyunsaturated Fatty Acids in Patients With Episodic Migraine N/A
Completed NCT04031781 - The Role of Left Prefrontal Transcranial Magnetic Stimulation in Episodic Migraine Prophylaxis N/A
Completed NCT05264129 - Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine Phase 4
Completed NCT04740827 - Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. Phase 3